Technology area: Biotechnology & Pharmaceuticals
35 pending office actions • 25 art units • 33 examiners • 0 of 35 (0%) have an AI response strategy ready • 32 patents granted in the last 365 days
Yeda Research and Development Co. Ltd. has 36 pending office actions in Biotechnology & Pharmaceuticals. The docket reaches 34 distinct examiners and 26 distinct art units, making it broadly distributed across both examination personnel and technical groups.
CELESTINE, NYROBI I is the busiest examiner, with 2 pending matters. That limited concentration places emphasis on portfolio-wide systems rather than management through a single examiner relationship. Counsel should maintain centralized oversight of scientific support, claim terminology, and response deadlines while adapting prosecution tactics to the 26 art units.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 10 (29%) |
| §103 only | 2 (6%) |
| §112 only | 4 (11%) |
| Double-patenting + other | 5 (14%) |
| Multi-statute (no §101) | 14 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CELESTINE, NYROBI I | 2 | 81.4% | +23.1% |
| WILLIAMS, KEITH RICHARD | 2 | 50.0% | +0.0% |
| DAVIS, AMELIE R | 1 | 65.1% | +33.2% |
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
| WEBSTER, KARMEL JOHANNA | 1 | 70.4% | +27.8% |
| SHELTON, SYNPHANE LA'SHAWN | 1 | 100.0% | +0.0% |
| PIPIC, ALMA | 1 | 54.8% | +54.3% |
| PAHAKIS, MANOLIS Y | 1 | 70.0% | +47.9% |
| MURESAN, ANA Z | 1 | 75.0% | +31.2% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18048873 | SYSTEM AND METHOD FOR ULTRASOUND ANALYSIS | CELESTINE, NYROBI I | 2d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18224345 | NON-PROTEIN PHENYLALANINE ANALOGUES FOR INHIBITING CYANOBACTERIA AND PLANT GROWTH | LIU, SUE XU | 168d overdue |
| 17614563 | ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | IVICH, FERNANDO NMN | 168d overdue |
| 18106903 | TREATMENT OF AN ISCHEMIC HEART DISEASE | TAYLOR, LIA ELAN | 121d overdue |
| 18281341 | ACYL ACTIVATING ENZYME AND A TRANSGENIC CELL, TISSUE, AND ORGANISM COMPRISING SAME | SPEED, DEQUANTARIUS JAVON | 117d overdue |
| 17958516 | METHODS OF DIAGNOSING CANCER AND PREDICTING RESPONSIVENESS TO THERAPY | SWITZER, JULIET CAROLINE | 72d |
| 19557236 | SYSTEM AND METHOD FOR PROCESSING ULTRASOUND IMAGES | DAVIS, AMELIE R | — |
| 19001657 | SYSTEM AND METHOD FOR DETECTING A CARDIAC ANOMALY | CELESTINE, NYROBI I | — |
| 18942735 | COMMENSAL FUNGUS AND USES THEREOF | KELLY, ROBERT M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18048873 | SYSTEM AND METHOD FOR ULTRASOUND ANALYSIS | CELESTINE, NYROBI I | 2d overdue |
| 19557236 | SYSTEM AND METHOD FOR PROCESSING ULTRASOUND IMAGES | DAVIS, AMELIE R | — |
| 19001657 | SYSTEM AND METHOD FOR DETECTING A CARDIAC ANOMALY | CELESTINE, NYROBI I | — |
| 18942735 | COMMENSAL FUNGUS AND USES THEREOF | KELLY, ROBERT M | — |
| 18859560 | DIAGNOSING AND TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | WEBSTER, KARMEL JOHANNA | — |
| 18792590 | DRUG-LOADED LIPOSOMES AND USES THEREOF IN TREATING BIOFILM | PIPIC, ALMA | — |
| 18726614 | PHOTODYNAMIC THERAPY SYSTEM AND METHOD | PAHAKIS, MANOLIS Y | — |
| 18692847 | PROCESS FOR THE PREPARATION OF THE SALBUTAMOL INTERMEDIATE | MURESAN, ANA Z | — |
| Art Unit | Apps |
|---|---|
| 1663 | 3 |
| 1644 | 3 |
| 3798 | 2 |
| 1652 | 2 |
| 1641 | 2 |
| 1616 | 2 |
| 1678 | 2 |
| 1645 | 2 |
| 3715 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19557236 | SYSTEM AND METHOD FOR PROCESSING ULTRASOUND IMAGES | DAVIS, AMELIE R | 3715 | §102§103§112Other | Non-Final OA | — | Pending | Mar 05, 2026 |
| 19001657 | SYSTEM AND METHOD FOR DETECTING A CARDIAC ANOMALY | CELESTINE, NYROBI I | 3798 | §101§102§103Other | Final Rejection | — | Pending | Dec 26, 2024 |
| 18942735 | COMMENSAL FUNGUS AND USES THEREOF | KELLY, ROBERT M | 1638 | §101§112 | Non-Final OA | — | Pending | Nov 10, 2024 |
| 18859560 | DIAGNOSING AND TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER | WEBSTER, KARMEL JOHANNA | 3792 | §101§102§103 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18855903 | ALCOHOL ACYLTRANSFERASE AND A TRANSGENIC CELL, TISSUE, AND ORGANISM COMPRISING SAME | SHELTON, SYNPHANE LA'SHAWN | 1652 | §101§112DP | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18851662 | URIDINE DIPHOSPHATE-GLYCOSYLTRANSFERASE AND A TRANSGENIC CELL, TISSUE, AND ORGANISM COMPRISING SAME | WILLIAMS, KEITH RICHARD | 1663 | §101§102§112Other | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18845798 | TRANSGENIC HELICHRYSUM UMBRACULIGERUM CELL, TISSUE, OR PLANT | WILLIAMS, KEITH RICHARD | 1663 | §103§112 | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18792590 | DRUG-LOADED LIPOSOMES AND USES THEREOF IN TREATING BIOFILM | PIPIC, ALMA | 1617 | §103§112 | Final Rejection | — | Pending | Aug 02, 2024 |
| 18726614 | PHOTODYNAMIC THERAPY SYSTEM AND METHOD | PAHAKIS, MANOLIS Y | 3796 | §102§103 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18692847 | PROCESS FOR THE PREPARATION OF THE SALBUTAMOL INTERMEDIATE | MURESAN, ANA Z | 1692 | §103§112 | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18692039 | MULTISPECIFIC ANTIBODIES FOR USE IN TREATING DISEASES | GUSTILO, ESTELLA M | 1646 | §102§103§112DPOther | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18106903 | TREATMENT OF AN ISCHEMIC HEART DISEASE | TAYLOR, LIA ELAN | 1641 | §103§112Other | Final Rejection | 121d overdue | Pending | Mar 08, 2024 |
| 18688809 | SPIKY METAL STRUCTURES | BRAZIN, JACQUELINE | 1798 | §102§103 | Non-Final OA | — | Pending | Mar 04, 2024 |
| 18444698 | ELECTRODE COMPRISING CARBON NANOTUBES AND AROMATIC COMPOUNDS AND PROCESS OF PREPARATION THEREOF | THOMAS, BRENT C | 1724 | §102§103 | Non-Final OA | — | Pending | Feb 18, 2024 |
| 18292946 | IRON-CATALYZED METATHESIS POLYMERIZATION OF OLEFINS | BROOKS, KREGG T | 1764 | §102§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
| 18421666 | EX-VIVO CULTURE SYSTEM AND METHODS OF USING SAME | ZHANG SPIERING, DONGXIU | 1616 | §103 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18408385 | T-CELLS COMPRISING ANTI-CD38 AND ANTI-CD138 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | BUNNER, BRIDGET E | 1647 | §112DP | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18535960 | Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18522466 | ANTI-MICROBIAL PEPTIDE (AMP) SIGNATURES FOR DIAGNOSTICS, STRATIFICATION, AND TREATMENT OF MICROBIOME-ASSOCIATED DISEASE | SVEIVEN, MICHAEL CAMERON | 1678 | §101§102§103 | Non-Final OA | — | Pending | Nov 29, 2023 |
| 18281536 | PRENYLTRANSFERASE AND A TRANSGENIC CELL, TISSUE, AND ORGANISM COMPRISING SAME | PAK, YONG D | 1652 | §101§112DP | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18281341 | ACYL ACTIVATING ENZYME AND A TRANSGENIC CELL, TISSUE, AND ORGANISM COMPRISING SAME | SPEED, DEQUANTARIUS JAVON | 1663 | §101§103§112 | Non-Final OA | 117d overdue | Pending | Sep 11, 2023 |
| 18234902 | GENETICALLY MODIFIED BACTERIA FOR GENERATING VACCINES | DUFFY, PATRICIA ANN | 1645 | §102§103§112 | Non-Final OA | — | Pending | Aug 17, 2023 |
| 18224345 | NON-PROTEIN PHENYLALANINE ANALOGUES FOR INHIBITING CYANOBACTERIA AND PLANT GROWTH | LIU, SUE XU | 1616 | §103§112 | Final Rejection | 168d overdue | Pending | Jul 20, 2023 |
| 18140095 | AGENTS BINDING MODIFIED ANTIGEN PRESENTED PEPTIDES AND USE OF SAME | BEVERIDGE, CONNOR HAMMOND | 1687 | §101§103 | Non-Final OA | — | Pending | Apr 27, 2023 |
| 18107573 | MAGE-A1 SPECIFIC T CELL RECEPTOR AND USES THEREOF | DUNN, LINDSAY MICHELLE | 1644 | §112 | Non-Final OA | — | Pending | Feb 09, 2023 |
| 18048873 | SYSTEM AND METHOD FOR ULTRASOUND ANALYSIS | CELESTINE, NYROBI I | 3798 | §103 | Final Rejection | 2d overdue | Pending | Oct 24, 2022 |
| 17958516 | METHODS OF DIAGNOSING CANCER AND PREDICTING RESPONSIVENESS TO THERAPY | SWITZER, JULIET CAROLINE | 1682 | §101§102§103§112 | Non-Final OA | 72d | Pending | Oct 03, 2022 |
| 17870876 | MULTISPECIFIC ANTIBODIES FOR USE IN TREATING DISEASES | LUNDE, GRACE HENRY | 1641 | §103§112DP | Final Rejection | — | Pending | Jul 22, 2022 |
| 17794268 | ARTICLES OF MANUFACTURE COMPRISING ANTI PD-L1 ANTIBODIES AND THEIR USE IN THERAPY | DRISCOLL, MAUREEN VARINA | 1644 | §103§112 | Non-Final OA | — | Pending | Jul 21, 2022 |
| 17839667 | MICROFLUIDIC DEVICE FOR ANALYZING GENE EXPRESSION | MARVICH, MARIA | 1634 | §112 | Final Rejection | — | Pending | Jun 14, 2022 |
| 17779704 | CHIMERIC ANTIGEN RECEPTOR TO CARBOHYDRATE ANTIGENS | DONOGHUE, BRITTNEY ERIN | 1675 | §112DP | Final Rejection | — | Pending | May 25, 2022 |
| 17614563 | ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | IVICH, FERNANDO NMN | 1678 | §103§112Other | Final Rejection | 168d overdue | Pending | Nov 29, 2021 |
| 17612279 | IDENTIFICATION OF RECURRENT MUTATED NEOPEPTIDES | FAUST, AMBER KATHLEEN | 1643 | §112 | Non-Final OA | — | Pending | Nov 18, 2021 |
| 16885331 | CONDITIONING PROTOCOLS AND USE OF SAME FOR TISSUE REGENERATION | MARTIN, PAUL C | 1653 | §103§112 | Final Rejection | — | Pending | May 28, 2020 |
| 16331863 | THERMOSTABLE VARIANTS OF P. FALCIPARUM PFRH5 WHICH CAN BE PRODUCED IN BACTERIAL CELLS | ZEMAN, ROBERT A | 1645 | §112 | Non-Final OA | — | Pending | Mar 08, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYeda Research and Development Co. Ltd. has 35 pending office actions as of October 2026, spread across 25 art units and 33 examiners.
Nyrobi I Celestine has the most, with 2 of Yeda Research and Development Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
